Production of Clinical Grade Mesenchymal Stromal Cells

Pytlík,; Slanař,; Stehlík,; Matějkova,

doi:10.5772/22428

Cited by 4 publications

(5 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDGFs were first found in platelets and they might be responsible for some of the platelet lysate activity in MSC growth. PDGFs have a role in osteogenic, adipogenic, and chondrogenic differentiation of MSCs; however, the primary effect is likely to be mitogenic action with inhibition of differentiation [ 39 ]. The PDGF-BB isoform can activate all PDGF receptors and therefore may be the best choice as a culture supplement.…”

Section: Expansion Of Mscsmentioning

confidence: 99%

Mesenchymal Stem Cells for Regenerative Therapy: Optimization of Cell Preparation Protocols

Ikebe

Suzuki

2014

BioMed Research International

179

133

View full text Add to dashboard Cite

Administration of bone marrow-derived mesenchymal stem cells (MSCs) is an innovative approach for the treatment of a range of diseases that are not curable by current therapies including heart failure. A number of clinical trials have been completed and many others are ongoing; more than 2,000 patients worldwide have been administered with culture-expanded allogeneic or autologous MSCs for the treatment of various diseases, showing feasibility and safety (and some efficacy) of this approach. However, protocols for isolation and expansion of donor MSCs vary widely between these trials, which could affect the efficacy of the therapy. It is therefore important to develop international standards of MSC production, which should be evidence-based, regulatory authority-compliant, of good medical practice grade, cost-effective, and clinically practical, so that this innovative approach becomes an established widely adopted treatment. This review article summarizes protocols to isolate and expand bone marrow-derived MSCs in 47 recent clinical trials of MSC-based therapy, which were published after 2007 onwards and provided sufficient methodological information. Identified issues and possible solutions associated with the MSC production methods, including materials and protocols for isolation and expansion, are discussed with reference to relevant experimental evidence with aim of future clinical success of MSC-based therapy.

show abstract

Section: Expansion Of Mscsmentioning

confidence: 99%

Mesenchymal Stem Cells for Regenerative Therapy: Optimization of Cell Preparation Protocols

Ikebe

Suzuki

2014

BioMed Research International

179

133

View full text Add to dashboard Cite

show abstract

“…Some factors promoting cell division may elicit unwanted bystander impacts that could act on certain signaling pathways. The mitogen PDGF, for instance, could indirectly prevent the differentiation of MSCs (Pytlík et al, 2011). Furthermore, it has been shown that the addition of b-FGF could trigger a dose-dependent upregulation of histocompatibility markers, especially that of class I molecules (Sotiropoulou et al, 2006).…”

Section: Current Strategies To Trigger the Proliferation Of Mscsmentioning

confidence: 99%

Electromagnetic field exposure as a plausible approach to enhance the proliferation and differentiation of mesenchymal stem cells in clinically relevant scenarios

Hamid

Sarmadi

Prasad

et al. 2022

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Mesenchymal stem/stromal cell (MSC)-based therapy has been regarded as one of the most revolutionary breakthroughs in the history of modern medicine owing to its myriad of immunoregulatory and regenerative properties. With the rapid progress in the fields of osteo- and musculoskeletal therapies, the demand for MSC-based treatment modalities is becoming increasingly prominent. In this endeavor, researchers around the world have devised new and innovative techniques to support the proliferation of MSCs while minimizing the loss of hallmark features of stem cells. One such example is electromagnetic field (EMF) exposure, which is an alternative approach with promising potential. In this review, we present a critical discourse on the efficiency, practicability, and limitations of some of the relevant methods, with insurmountable evidence backing the implementation of EMF as a feasible strategy for the clinically relevant expansion of MSCs.

show abstract

“…This allows their preparation in suitable transfusion or blood banking facilities. 69 The ATMP regulation has been differently managed worldwide; the EU and the United States have implemented new systems for the regulation of ATMPs that intend to merge, as much as possible, the regulatory requirements worldwide. 70 In the EU, the European Medicines Agency (EMA) established a Committee for Advanced Therapies (CAT) (in accordance to 1394/2007).…”

Section: Overview Of Regulatory Aspects For Clinical Applicationmentioning

confidence: 99%